US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify ...

Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx ...

ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC

"ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC" was originally created and published by ...
Business Wire

Foundation Medicine to Present Over 15 Abstracts at the 2025 ASCO ® Annual Meeting

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomic company committed to transforming cancer care, today announced that the company and its collaborators will present more than 15 abstracts ...